EBC-46

Consumer Reports

Tincture Taste Profile: What EBC-46 Blushwood Berry Users Describe and How It Shifts Between Batches

Blushwood berry tincture has a recognisable taste profile that varies with batch and carrier solvent. Here is what experienced EBC-46 users report about flavour, aftertaste, and palatability.

Mechanism of Action

Ferroptosis and EBC-46: How Tigilanol Tiglate Intersects With Iron-Dependent, Lipid-Peroxidation Cell Death

Ferroptosis is an iron-dependent form of regulated cell death driven by lipid peroxidation. This article reviews the evidence linking EBC-46 mechanism studies to ferroptotic signalling.

Regulatory

India CDSCO and AYUSH Frameworks: How EBC-46 Blushwood Berry Supplements Are Classified

India regulates botanical supplements through CDSCO and the Ministry of AYUSH. This explainer shows where EBC-46 blushwood berry products sit in that framework in 2026.

Consumer Reports

First-Open Headspace and Post-Opening Oxidation of Blushwood Berry Tinctures: User Reports on Bottle Life After Seal Break

What users report about how blushwood berry tincture stability changes after the first opening, and how headspace oxygen, light, and refrigeration interact during normal use.

Botany

Water Relations and Drought Tolerance in Fontainea picrosperma: Hydraulic Constraints on Blushwood Cultivation

How leaf-level water potential, stomatal regulation, and xylem hydraulics shape the cultivation envelope for Fontainea picrosperma, the blushwood berry tree behind EBC-46.

Human Trials

Circulating Tumour DNA (ctDNA) as a Pharmacodynamic Biomarker in Tigilanol Tiglate (EBC-46) Clinical Trials

How ctDNA / liquid biopsy is emerging as a dynamic biomarker for monitoring early response, residual disease, and recurrence in tigilanol tiglate (EBC-46) clinical trials.

Mechanism of Action

Heat Shock Protein Response and EBC-46: How Tigilanol Tiglate Engages HSP70 and HSP90 Chaperone Networks

How the cellular stress response system — including HSP70 and HSP90 chaperones — interacts with tigilanol tiglate (EBC-46) signalling, and what this means for tumour cell death cascades.

Regulatory

China's NMPA Health Food (保健食品) Framework: How EBC-46 Botanical Supplements Would Be Classified

How China's NMPA classifies imported botanicals under the Health Food (Bao Jian Shi Pin) framework and what this means for EBC-46 supplements seeking market entry.

Human Trials

Adverse Event Profile in Tigilanol Tiglate Phase 2 Trials: Local Versus Systemic Effects

Published Phase 2 human trial data for intratumoural tigilanol tiglate shows a distinctive safety signature: predominantly local, transient, and rarely systemic.

Mechanism of Action

PKC Isoform Selectivity: How Tigilanol Tiglate Distinguishes Between Protein Kinase C Subtypes

Tigilanol tiglate, the active compound EBC-46, activates multiple PKC isoforms but does so with measurable selectivity. Here is what the kinase data shows.

Regulatory

Health Canada Natural Health Products: How EBC-46 Supplements Are Classified in 2026

How Health Canada's Natural Health Products Regulations classify blushwood berry extract supplements, the NPN licensing pathway, and what buyers should know.

Human Trials

RECIST Response Criteria in Tigilanol Tiglate Trials: How Tumour Response Is Actually Measured

RECIST 1.1 is the standard framework for measuring tumour response in clinical trials. Here is how it applies — and where it falls short — for intratumoural agents like tigilanol tiglate.